上海建瓴

四川多瑞药业有限公司的艾可宁原料药生产线已顺利通过药品GMP核查，这一认证标志着生产线符合国家药品生产质量管理规范，具备了生产资质和商业化生产能力。随着该生产线全面启动，多瑞医药的原料药业务将进入新的发展阶段。

上海前沿建瓴生物科技有限公司是前沿生物的原料药子公司，是一家从事化学药品制剂及其原料药的研发、生产和销售工作的医药企业。

This company profile has not been updated since December 2020, when Clene Nanomedicine merged with Tottenham Acquisition I to form Clene.Clene Nanomedicine is a subsidiary of Clene Inc was focused on developing nanotherapeutic medicines for the treatment of bioenergetic failure associated with neurodegenerative diseases. Clene created a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs.In September 2021, Tottenham Acquisition I Limited announced that it has entered into a definitive merger agreement for a business combination with Clene Nanomedicine, Inc.In August 2021, Clene, Inc and Clene Nanomedicine, Inc announced the completion of two lease agreements.In September 2020, Tottenham Acquisition I entered into a definitive merger agreement with Clene Nanomedicine. Tottenham would reincorporate to the state of Delaware by merging with and into Chelsea Worldwide, a Delaware company and wholly owned subsidiary of